NCT02014714

Brief Summary

Obstructive Sleep Apnea (OSA) is a common clinical problem with a reported prevalence of 2% to 4% in the general population. The incidence was double on patients who had a diagnosis of OSA going for orthopedics surgery. Little literature composed mostly of case reports or small retrospective case-control studies exist examining the use of intrathecal opioids on outcomes in OSA patients is inconclusive. The primary objective of this study is to compare the post operative respiratory effect after single dose intrathecal morphine and intrathecal fentanyl on orthopedics patients who suspected or undiagnosed obstructive sleep apnea. Hypotheses Undiagnosed OSA patients who received intrathecal morphine are more likely to have respiratory events post-operatively.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P50-P75 for phase_1

Timeline
Completed

Started Dec 2013

Shorter than P25 for phase_1

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2013

Completed
11 days until next milestone

First Submitted

Initial submission to the registry

December 12, 2013

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 18, 2013

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2014

Completed
Last Updated

December 19, 2013

Status Verified

December 1, 2013

Enrollment Period

6 months

First QC Date

December 12, 2013

Last Update Submit

December 18, 2013

Conditions

Outcome Measures

Primary Outcomes (3)

  • Respiratory Rate (RR)

    The end point of the study is to assess the respiratory rate (RR) within 72 hours post-operatively in both arms of the patients.

    72 hours post operatively

  • Heart Rate (HR)

    The end point of the study is to assess the heart rate (HR) within 72 hours post-operatively in both arms of the patients.

    72 hours post-operative

  • Oxygen Desaturation Index (ODI)

    The end point of the study is to assess the Oxygen Desaturation Index (ODI) within 72 hours post-operatively in both arms of the patients.

    72 hours post-operative

Study Arms (2)

Morphine

ACTIVE COMPARATOR

Intrathecal Morphine 0.1mg

Drug: Morphine

Fentanyl

ACTIVE COMPARATOR

Intrathecal Fentanyl 40mcg

Drug: Fentanyl

Interventions

Drug: Morphine Depending on the randomization schedule, 0.1mg of morphine or will be added to the intrathecal mixture.

Morphine

Drug: Fentanyl 40mcg Depending on the randomization schedule, 40μg of fentanyl will be added to the intrathecal mixture.

Also known as: Fentanyl-hameln
Fentanyl

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18
  • ASA I - II
  • Patients who admitted for orthopedic surgery and consented for regional anesthesia
  • STOP - BANG score ≥ 5

You may not qualify if:

  • Refused to give informed consent
  • Previous diagnosis and treatment of OSA or any sleep-related breathing disorder
  • Allergic to morphine / fentanyl / Local anesthetic
  • Contra-indicated for regional anesthesia
  • Pregnant woman
  • Contraindication to either of the oral analgesia as in protocol

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Malaya Medical Centre

Kuala Lumpur, Kuala Lumpur, 50603, Malaysia

RECRUITING

MeSH Terms

Interventions

MorphineFentanyl

Intervention Hierarchy (Ancestors)

Morphine DerivativesMorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic CompoundsPiperidinesHeterocyclic Compounds, 1-Ring

Study Officials

  • Wang Chew Yin

    University of Malaya

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 12, 2013

First Posted

December 18, 2013

Study Start

December 1, 2013

Primary Completion

June 1, 2014

Study Completion

June 1, 2014

Last Updated

December 19, 2013

Record last verified: 2013-12

Locations